News for Moderna, Inc. (M1RN34.SA)

Moderna, Inc. (NASDAQ:MRNA) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ETCompany ParticipantsStéphane Bancel - CEO &...

Moderna Inc. (MRNA) experienced a minor dip in its stock price, falling by 22 cents to approximately $27.92. Despite the decline, the options trading atmosphere

(Bloomberg) -- This year’s stock market turbulence has punished ordinary investors. But for the wealthy, it’s opened up fresh opportunities to convert equity swings into tax breaks — fueling a growing Wall Street business that turns volatility into a financial advantage. Most Read from BloombergTrump Said He Fired the National Portrait Gallery Director. She’s Still There.NYC Mayoral Candidates All Agree on Building More Housing. But Where?Senator Calls for Closing Troubled ICE Detention Facility

Moderna, Inc. (NASDAQ:MRNA) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ETCompany ParticipantsStephen Hoge - PresidentConference Call...

Long-established in the Biotechnology industry, Moderna Inc (MRNA) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 1.26%, j

Moderna's new placebo-controlled trial aims to expand its recently approved mNEXSPIKE vaccine. Analysts project a significant 68.46% upside potential fo

Moderna (MRNA) finds itself navigating a challenging landscape as it relies heavily on its mRNA technology, which was instrumental in the development of its COV

Moderna (MRNA) finds itself in a challenging situation as it has heavily invested in the development of mRNA-based treatments and vaccines. While the company ac

Moderna (MRNA) experiences a 7% stock increase after FDA approves its new COVID-19 vaccine, mNEXSPIKE. Analysts offer mixed price targets, with a potent

Shares of Moderna, Inc. were gaining around 5 percent in the pre-market activity on the Nasdaq after its new Covid-19 vaccine, mNEXSPIKE, received approval from the U.

Moderna (MRNA) has secured approval from the U.S. Food and Drug Administration for its latest COVID-19 vaccine, mNEXSPIKE. This new vaccine is now cleared for u

Moderna secures FDA approval for the innovative mNEXSPIKE COVID-19 vaccine. Analysts predict a 76.39% upside potential for Moderna's stock. GuruFocus

mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S

Moderna (MRNA) receives FDA approval for its third product, the mNEXSPIKE COVID-19 vaccine. mNEXSPIKE shows 9.3% higher efficacy compared to the origina

As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. The following biotech companies are awaiting potential approvals in June 2025.

Moderna, Inc. (NASDAQ:MRNA) Bernstein 41st Annual Strategic Decisions Conference Call May 29, 2025 10:00 AM ETCompany ParticipantsStephane Bancel - CEO...

Key Takeaways: Moderna's premarket trading remains unchanged despite a significant contract cancellation. Analysts' mixed forecasts present both potentia

BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant ( ROIV) today reported its financial results for the fourth quarter and f

Moderna, Inc.